Evidence map›Paper›PMID 35156569›Full record

ReviewCurrent medicinal chemistry2023

Aptamer-based Emerging Tools for Viral Biomarker Detection: A Focus on SARS-CoV-2.

Prabir Kumar Kulabhusan, Parsa Pishva, Eda Çapkın, Prajakta Tambe, Meral Yüce

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Prabir Kumar KulabhusanInstitute for Global Food Security, School of Biological Sciences, Queen's University Belfast, Belfast, UK.
Parsa PishvaSabanci University, Faculty of Engineering and Natural Sciences, Istanbul, 34956, Turkey.
Eda ÇapkınSabanci University, Faculty of Engineering and Natural Sciences, Istanbul, 34956, Turkey.
Prajakta TambeWellcome-- Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.
Meral YüceSabanci University, SUNUM Nanotechnology Research, and Application Centre, Istanbul, 34956, Turkey.
Sabancı Üniversitesi · TRQueen's University Belfast · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viral infections can cause fatal illnesses to humans as well as animals. Early detection of viruses is therefore crucial to provide effective treatment to patients. Recently, the Covid-19 pandemic has undoubtedly given an alarming call to develop rapid and sensitive detection platforms. The viral diagnostic tools need to be fast, affordable, and easy to operate with high sensitivity and specificity equivalent or superior to the currently used diagnostic methods. The present detection methods include direct detection of viral antigens or measuring the response of antibodies to viral infections. However, the sensitivity and quantification of the virus are still a significant challenge. Detection tools employing synthetic binding molecules like aptamers may provide several advantages over the conventional methods that use antibodies in the assay format. Aptamers are highly stable and tailorable molecules and are therefore ideal for detection and chemical sensing applications. This review article discusses various advances made in aptamer-based viral detection platforms, including electrochemical, optical, and colorimetric methods to detect viruses, specifically SARS-Cov-2. Considering the several advantages, aptamers could be game-changing in designing high-throughput biosensors for viruses and other biomedical applications in the future.

Indexed as

Aptamers, NucleotideCOVID-19VirusesAnimalsAntibodiesBiomarkersHumansPandemicsSARS-CoV-2AntibodiesAptamers, NucleotideBiomarkersAptamersbiomarkersbiosensorsMERS-CoVSARS-CoV-2viruses

Identifiers

PMID35156569
OpenAlexW4213083428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.